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Genetic factors are known to influence host resistance to certain tumors . In the
mouse, resistance has been linked to theMHC locus on chromosome 17 (1-4) . H-2
genes or other closely linked genes may be responsible, and natural resistance to
transplantable lymphomas represents one casewhere these two possibilities have not
been resolved (5) . A distinct set of H-2-linked "hemopoietic histocompatibility"
(Hh)' antigens has been postulated to explain the competence to reject small lym-
phoma grafts (5) . We have used the transgenic strain D8 (6) to analyze the genetic
control of host resistance to tumors. The transgenic mouse D8 was generated by
introducing an 8.0-kb genomic fragment containing the H-2Dd gene and 2 .5-kb 5'
and 2.0-kb 3' flanking sequences into C57BL/6 (B6) zygotes (6). The transgene product
was expressed in different tissues in the same way as the endogenous H-2b haplo-
type products, without alterations in the expression of the latter (6, 7) . The expressed
antigen was also recognized as self, and could function as a restriction element for
T cells (7) . We here report that the D8 mice have acquired "natural" resistance to
C57BL lymphoma grafts in parallel with expression of the transgene product .
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Materials and Methods
Mice.
￿
All strains and crosses were bred and maintained in the animal facilities oftheJohns
Hopkins University (Baltimore, MD) or at the Karolinska Institute (Stockholm, Sweden) .
The D8 transgenic strain was described previously (6) . The C57BL/6 (B6) mice from which
the D8 line was derived, as well as the original breeders of B10 congenic strains, were from
the Jackson Laboratory, Bar Harbor, ME . B6 mice were also purchased fromALAB, Sollen-
tuna, Sweden .
Tumors.
￿
RBL-5MA is a subline of the Raucher virus-induced T cell lymphoma RBL-5
of B6 origin (8) . P52-127 .166 and EL-4 (both T cell lymphomas of B6 origin) were induced
by RAD-LV and benzpyrene, respectively. All tumors were maintained as ascites lines in
the syngeneic strain .
Tumor Growth Experiments.
￿
Graded doses ofRBL-5MA ascites cells were inoculated sub-
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cutaneously into the right flank of age-matched mice. The growth of the solid tumors was
followed by weekly palpations. Tumors grew equally well in B6 mice ofthe National Institutes
of Health (Bethesda, MD) colony, the progenitor strain of the transgenic mice, and B6 mice
from the Stockholm colony, our usual host for the serial transplantation of the RBL-5
lymphoma.
In Vivo NK Cell Depletion.
￿
1 d before inoculation of tumor cells, each mouse either re-
ceived an intravenous dose of 30 wl anti-asialo GM, antiserum, or an intraperitoneal injec-
tion of 200 ul anti-NK 1.1 mAb (ascites preparation) (8). In the case of anti-asialo GM, an-
tiserum, the mice received additional inoculations on day 3 and 7 aftertumor cell inoculation.
In Vitro H-2 Typing.
￿
(D8 x B6)F, x B6 backcross mice were typed for expression of the
D° antigen by a one step complement-dependent cytotoxicity test. The 34-5-8S (anti Dd)
mAb, (obtained from the American Type Culture Collection, Rockville, MD) was used on
inguinal lymphnode cells removed during general anesthesia. All mice that showed >50%
specific killing were typed as Dd. . The majority of mice typed as positive showed >80% dead
cells, while the majority of mice typed as negative showed <20% dead cells. Of 126 mice
typed so far, 63 have been found Dd' and 63 Dd- .
Results and Discussion
Tumor growth was followed after subcutaneous inoculation ofgraded doses ofRBL-5
lymphoma cells (H-2b) in mice of the C57BL/6 (B6) strain and of the H-21)d trans-
genic strain D8. Transgenic D8 mice were more resistant to inocula of 103 and 104
cells than the B6 mice (Table I). F1 hybrids between D8 and B6 were all Dd' and
rejected the RBL-5 lymphoma in a similar fashion as D8.
Tumor resistance segregated with Dd in (D8 x B6)F1 x B6 backcross mice. An
inoculum of 104 cells grew out as tumors in 3 of 18 Dd' and in 17 of 18 Dd- back-
cross mice (Fig. 1). The 1 :1 distribution confirmed that the transgene segregated
as a single dominant gene (6). The integration site of the transgene is unknown,
but linkage analysis studies have excluded a location site within or near the MHC (9).
It has been previously found that the RBL-5 tumor is sensitive to Fl hybrid re-
sistance (10), defined as the rejection of transplanted hematopoietic tissue or tumors
of parental origin by F1 hybrids of two inbred strains (1, 5). RBL-5 cells were re-
jected by all F1 hybrids and all backcross mice that carried the Dd gene (10, Table
I). As shown by the dose titration experiments, (D8 x B6)Fl hybrids and B6 to con-
genic H-2D' strain F1 hybrids rejected RBL-5 cells equally well (Table I).
Resistance of the Dd' backcross mice could be completely abrogated by either
400 rad irradiation or by anti-asialo GM, antibody treatment (Fig. 1). The same
treatments are known to abrogate NK cell-mediated H-2-associated resistance to
RBL-5 in conventional F1 and backcrosses, while T cell depletion by thymectomy
and irradiation has no effect (11-13). This suggests that NK cells are involved, which
was confirmed here for the rejection in transgenic mice by treatment of the animals
with the mAb anti-NK 1.1 (8, 14). The tumors then grew equally well in D8, (D8
x B6)Fl, and B6 mice (Table I). (D8 x B6)F1 hybrids were also resistant to
threshold doses of two other B6 lymphomas, the rad-LVinduced P52-127.166 and
the benzpyrene-induced EL-4 (Table I). Our results with the D8 mice, and the as-
sociation between resistance and Dd in the H-2-recombinant crosses lead to the con-
clusion that the lymphoma resistance is directly dependent on the Dd gene.
Apart from demonstrating that tumorrejection could be conveyed by a transgene,
the results are pertinent for the interpretation of the MHC-linked control of Fl hy-
brid resistance. Recessive Hh antigens have been postulated to explain hybrid resis-tance to hematopoietic grafts (5). TheHh genes have been tentatively located to the
D region of the H-2 complex, although rejection did not require expression of the
136 antigen on the graft (5, 15-17). It was suggested that the H-26-linked Hh-l' al-
lele is only expressed in the homozygous H-2616 parent that would be tolerant to
the corresponding antigen product. Heterozygous H-2d16 mice would not express
Hh-16, with lack oftolerance and rejection of a Hh-16+ lymphoma graft as the con-
100
60d
Y
UJ Bo-
p 40-
0-
HOGLUND ET AL.
￿
1471
TABLE I
Tumor Growth .after Subcutaneous Inoculation of RBL-5,
EL-4, and P52-127. 166 Lymphomas
Mice with tumors/inoculated mice.
1 p < 0.001 by
x2 tests, when compared with the relevant control, i.e., B6 in
the case oftransgenic and F1 hybrids and untreated controls of the same geno-
type in the case of anti-NK 1 .1-treated mice. No index means p > 0.05, i.e.,
NS.
5 p < 0.005.
O-O Control Dd-
￿
FIGURE 1.
￿
Effect ofirradiation
(29/31)
￿
or anti-asialo GM, treatment
"-" Control O+
￿
on growth of RBL-5 lymphoma
(3/16)
￿
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￿
backcross mice. The figure
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￿
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￿
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22
￿
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DAYS AFTER INOCULATION
￿
are shown in parentheses.
Tumors and strains
H-2 haplotype
K D Transgene
Tumor takes"
103 104 105
RBL-5 MA
136 6/b b/b -/- 31/38 68/68 50/50
D8 6/b b/b d/d 0/81 7/231 14/16
D8 x B6 6/b b/b d/- 0/151 7/271 22/24
B10A(5R) x B6 6/b b/d -/- 0/71 2/231 10/13
1310132 x B6 b/d b/d -/- 0/45 1/81 3/3
B10A x B6 6/k b/d -/- 1/4 0/101 5/6
B6, anti-NK1 .1 b/b b/b -/- - 16/16
D8, anti-NK1 .1 6/b b/b d/d - 9/95
D8 x 136, anti-NK1 .1 b/b b/b d/- - 8/81
EL-4
B6 b/b b/b -/- - 12/12 14/14
D8 x B6 b/b b/b d/- - 3/105 2/111
P52-127.166
B6 b/b b/b -/- - 16/18
D8 x B6 b/b b/b d/- - 0/1011472
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sequence (5). Our data do not address the role of the putative Hh gene products
as target antigens, and they do not exclude a role of such genes at the host level.
They could be under trans-acting control (16), regulated by sequences included in
the transgene. However, notranscripts havebeen detected from the flankingsequences
oftheDd gene carried by the construct (G.Jay, unpublished observation). It is there-
fore most likely that the Dd gene itself is responsible for the resistance of the D8
mice and of conventional Fl hybrids (10-12). Hybrid resistance models based on
MHC class I genes therefore deserve increased attention (18-23). Snell (20) has pro-
posed, long before NK cells were recognized as effector cells in hybrid resistance,
that MHC antigens ofthe effector cells could recognize an MHC mismatch on the
graft. This could lead to effector cell triggering and killing. To explain hybrid resis-
tance and certain in vitro observations on NKlysis, we have suggested amodel that
can be regarded as adevelopmentofSnell'sidea(22, 23). Subsequent totheirbinding
to the target cell, NK cells would sense the quantity of syngeneic MHC products
expressed by the target. This could occur viaan indirect mechanism, involving rec-
ognition ofepitopes modulatedby syngeneicMHC productsor viaadirect recogni-
tion ofthe latter. Adequate concentrationofclass I products would inhibit the trig-
gering ofNK lysis. This ability would be impaired in MHC-deficient variants (23),
leading to lysis. Under conditions ofincomplete host MHC expression (allogeneic
graft, parental graftinto Fl or transgenic host), the inactivation ofthe NK cell would
be only partial, leading to the rejection ofthe graft. The present results are consis-
tent with the predictions ofthis model. Introduction of a new class I allele into the
host was sufficient to turn graft acceptance into rejection, mediated by asialo GM1
and NK 1.1 positive cells. It is not clear whether these cells recognized the absence
of Dd themselves (22, 23), or acted less specifically, e. g., after the graft had been
mispositioned in the transgenic mice by the action ofother host cells (24). It must
be stressed that NK cells may have multiple recognition strategies and surveillance
functions. Other NK-mediated host-graft orhost-virus (25) interactions may there-
fore be H-2 independent. Furthermore, a system scanning for absence ofselfmust
not necessarily distinguish class I epitopes by the same criteria as T cells, which
means that not every new H-2 allele introduced by an Fl cross or a transgene must
lead to an altered picture of self from the point of view of NK cells.
H-2-associated natural resistance as well as NK cells are effective in mice with
severe combined immunodeficiency (26, 27). These mice are defective with regard
to Igand TCR gene rearrangement (28). With the direct evidence that class I genes
are involved in natural resistance, one may ask if the MHC products have other
immunological functions than presentation ofpeptides to receptors assembled from
the a, Q, Y, and 8 TCR families. By the use of bone marrow chimera and exon-
shuffled genes, it may be possible to delineate the part of H-2D' required, and the
time and siteofits expression necessaryto switch off"tolerance" in anNK-dependent
system.
Summary
The H-2Dd transgenic strain D8 on C57BL background was more resistant to
subcutaneous challenge ofRBL-5 lymphoma cells than B6 controls. The direct role
of the H-2Dd antigen was investigated by the use of (D8 x B6)F1 crosses and (D8
B6) x B6 backcrosses. The latter showed cosegregation with regard to Dd antigenexpression and lymphoma resistance, both of which were inherited in a pattern con-
sistent with control by a single dominant gene. The rejection potential in (D8 x
B6)Fl mice appeared as strong as that seen in crosses between B6 and MHC con-
genic mice (on B10 background) carrying H-2V. The lymphoma resistance could
be abrogated by treatment with anti-asialo GM, antiserum or anti-NK 1 .1 mAb,
indicating a role for NK cells.
Receivedforpublication 17 May 1988.
HOGLUND ET AL.
￿
1473
References
1 . Snell, G. D., and L. C. Stevens. 1961. Histocompatibility genes of mice. III. H-1 and
H-4, two histocompatibility loci in the first linkage group. Immunology. 4:366.
2 . Tennant, J. R., and G. D. Snell. 1968. The H-2 locus and viral leukemogenesis as studied
in congenic strains of mice. J Natl. Cancer Inst. 41:597.
3 . Meruelo, D., M. Lieberman, N. Ginzton, B. Deak, and H. O. McDevitt. 1977. Genetic
control ofradiation leukemia virus-induced tumorigenesis. I. Role of the major murine
histocompatibility complex.J. Exp. Med. 146:1079.
4 . Ahrlund-Richter, L., C . Nordstedt, G. Klein, and E. Klein. 1985. Genetic studies on
natural resistance to Moloney lymphoma (YAC) isografts. Immunogenetics. 22:517.
5 . Cudkowicz, G. 1980. Natural resistance to foreign hematopoietic and leukemia grafts.
In Natural Resistance Systems Against Foreign Cells, Tumors and Microbes. G. Cud-
kowicz, M. Landy, and G. M. Shearer, editors. Academic Press, New York. 3-20.
6. Bieberich, C., G. Scangos, K. Tanaka, and G. Jay. 1986. Regulated expression of a mu-
rine class I gene in transgenic mice. Mol. Cel. Biol. 6:1339.
7 . Yoshioka, T., C . Bieberich, G. Scangos, and G. Jay. 1987. A transgenic class I antigen
is recognized as self and functions as a restriction element. J Immun. 139:3861.
8. Koo, G. C., and J. R. Peppard. 1984. Establishment of monoclonal anti NK 1.1 anti-
body. Hybridoma. 3:301.
9. Bieberich, C., T. Yoshioka, K. Tanaka, G. Jay, and G. Scangos. 1987. Functional expres-
sion of a heterologous major histocompatibility complex class I gene in transgenic mice.
Mol. Cel. Biol. 7:4003.
10. Klein, G. O., G. Klein, R. Kiessling, and K. Karre. 1978. H-2 associated control of
natural cytotoxicity and hybrid resistance against RBL-5 . Immunogenetics. 6:561.
11 . Karre, K., G. O. Klein, R. Kiessling, S. Argov, and G. Klein. 1982. The beige model
in studies of natural resistance to syngeneic, semisyngeneic and primary tumors. In NK
Cells and Other Natural Effector Cells. R. B. Herberman, editor. Academic Press, New
York. 1369-1378.
12. Klein, G. O., K. Karre, R. Kiessling, and G. Klein. 1982. Thymus-independence of
hybrid resistance against a panel of T-cell lymphomas of H-26 origin. Int. J. Cancer.
30:659.
13. Klein, G. O., and G. Klein. 1984. Immune resistance of semisyngeneic F, hybrid mice
to lymphoma grafts differs from natural hybrid resistance in its genetic pattern. Cell.
Immunol. 86:546.
14. Seaman, W E., M. Sleisenger, E. Eriksson, and G. C . Koo. 1987 . Depletion of natural
killer cells in mice by monoclonal antibody to NK-1.1. Reduction in host defence against
malignancy without loss of cellular or humoral immunity. J Immunol. 138:4539.
15. Clark, E. A., and R. C. Harmon. 1980. Genetic control of natural cytotoxicity and hy-
brid resistance. Adv. Cancer Res. 31:227.
16. Rembecki, R. N., M. Bennett, V. Kumar, and T. A. Potter. 1987. Expression of
hemopoietic histocompatibility antigen on H-2 loss variants of Fl hybrid lymphoma cells:1474
￿
NATURAL RESISTANCE TO C57BL LYMPHOMA GRAFTS IN MICE
evidence consistent with trans gene regulation. J Immunol. 138:2734.
17 . Milisauskas, V. K., S. G. Kaminsky, and I. Nakamura. 1987 . Class I H-2D' deter-
minants are not involved in hybrid resistance to parental H-2b/Hh-l b bone marrow al-
lograft. Eur. J. Immunol. 17:1043 .
18 . Hellstr6m, K. E., and I. Hellstr6m. 1967. Allogeneic inhibition of transplanted tumor
cells. Prog. Exp. Tumor Res. 9:40.
19 . M611er, G., and E. M611er. 1965. Plaque-formation by non-immune and X-irradiated
lymphoid cells on monolayers of mouse embryo cells. Nature (Loud.). 208:260.
20 . Snell, G. 1976. Recognition structures determined by the H-2 complex. Transplant. Proc.
8:147.
21 . Carlson, G. A., D. Melnychuk, and M. J. Meeker. 1980 . H-2 associated resistance to
leukemia transplantation: natural killing in vivo. Int. J Cancer. 25:111 .
22 . Karre, K. 1985. Role of target histocompatibility antigens in regulation of natural killer
activity: a reeavaluation and a hypothesis. In Mechanisms of Cytotoxicity by NK-cells.
R. B. Herberman and D. Callewaert, editors. Academic Press, New York. 81-91,
23. Karre, K., H. G. Ljunggren, G. Piontek, and R. Kiessling. 1986. Selective rejection
of H-2 deficient lymphoma variant suggests alternative immune defence strategy. Nature
(Loud.). 319:675.
24. Carlson, G. A., B. A. Taylor, S. T. Marshall, and A. H. Greenberg. 1984. A genetic
analysis of natural resistance to nonsyngeneic cells: the role ofH-2. Immunogenetics. 20:287.
25 . Moller, J. R., B. Rager-Zisman, P C . Quan, A. Schattner, D. Panush, J . K. Rose, and
B. R. Bloom. 1985. Natural killer cells recognition of target cells expressing different
antigens of vesicular stomatitis virus. Proc. Natl. Acad. Sci. USA. 82 :2456.
26 . Carlson, G. A., and S. P. Marshall. H-2 associated natural resistance against nonsyn-
geneic lymphoma cellsin mice with severe combined immunodeficiency. In Genetic Control
of Host Resistance to Infection and Malignancy. E. Shamene, editor. A. R. Liss Inc.,
New York. 701-712.
27 . Tutt, M. M., W. Schuler, A. Kuziel, P. W. Tucker, M. Bennett, M. J . Bosma, and V.
Kumar. 1987. J. Immunol. 138:2338.
28 . Schuler, W., I. J. Weiler, A. Schuler, R. A. Phillips, N. Rosenberg, T. W. Mak, J . F.
Kearney, R. P. Perry, and M. J. Bosma. 1986. Rearrangement ofantigen receptor genes
is defective in mice with severe combined immune deficiency. Cell. 46:963.